Media coverage
37
Media coverage
Title AbbVie Receives U.S. FDA Approval of MAVYRET™ (glecaprevir/pibrentasvir) for the Treatment of Chronic Hepatitis C in All Major Genotypes (GT 1-6) in as Short as 8 Weeks Media name/outlet PipelineReview Country Spain Date 8/4/17 Persons Fred Poordad Title AbbVie Receives U.S. FDA Approval of MAVYRET™ (glecaprevir/pibrentasvir) for the Treatment of Chronic Hepatitis C in All Major Genotypes (GT 1-6) in as Short as 8 Weeks Media name/outlet National AIDS Treatment Advocacy Project Country United States Date 8/4/17 Persons Fred Poordad Title AbbVie Receives U.S. FDA Approval of MAVYRET™ (glecaprevir/pibrentasvir) for the Treatment of Chronic Hepatitis C in All Major Genotypes (GT 1-6) in as Short as 8 Weeks Media name/outlet PR Newswire Country United States Date 8/3/17 Persons Fred Poordad Title ABBVIE : Receives U.S. FDA Approval of MAVYRET(TM) (glecaprevir/pibrentasvir) for the Treatment of Chronic Hepatitis C in All Major Genotypes (GT 1-6) in as Short as 8 Weeks Media name/outlet 4 Traders Country United States Date 8/3/17 Persons Fred Poordad Title AbbVie Receives U.S. FDA Approval of MAVYRET™ (glecaprevir/pibrentasvir) for the Treatment of Chronic Hepatitis C in All Major Genotypes (GT 1-6) in as Short as 8 Weeks Media name/outlet Ariva.de Country Germany Date 8/3/17 Persons Fred Poordad Title AbbVie Receives U.S. FDA Approval of MAVYRETâ„¢ (glecaprevir/pibrentasvir) for the Treatment of Chronic Hepatitis C in All Major Genotypes (GT 1-6) in as Short as 8 Weeks Media name/outlet TickerTech.com Country United States Date 8/3/17 Persons Fred Poordad Title AbbVie Receives U.S. FDA Approval of MAVYRET™ (glecaprevir/pibrentasvir) for the Treatment of Chronic Hepatitis C in All Major Genotypes (GT 1-6) in as Short as 8 Weeks Media name/outlet WTVM Country Georgia Date 8/3/17 Persons Fred Poordad Title AbbVie Receives U.S. FDA Approval of MAVYRET™ (glecaprevir/pibrentasvir) for the Treatment of Chronic Hepatitis C in All Major Genotypes (GT 1-6) in as Short as 8 Weeks Media name/outlet Live 5 WCSC Country United States Date 8/3/17 Persons Fred Poordad Title AbbVie Receives U.S. FDA Approval of MAVYRET™ (glecaprevir/pibrentasvir) for the Treatment of Chronic Hepatitis C in All Major Genotypes (GT 1-6) in as Short as 8 Weeks Media name/outlet WBOC TV 16 Country United States Date 8/3/17 Persons Fred Poordad Title AbbVie Receives U.S. FDA Approval of MAVYRET™ (glecaprevir/pibrentasvir) for the Treatment of Chronic Hepatitis C in All Major Genotypes (GT 1-6) in as Short as 8 Weeks Media name/outlet WMBF Country United States Date 8/3/17 Persons Fred Poordad Title AbbVie Receives U.S. FDA Approval of MAVYRET™ (glecaprevir/pibrentasvir) for the Treatment of Chronic Hepatitis C in All Major Genotypes (GT 1-6) in as Short as 8 Weeks Media name/outlet KAUZ Country United States Date 8/3/17 Persons Fred Poordad Title AbbVie Receives U.S. FDA Approval of MAVYRET™ (glecaprevir/pibrentasvir) for the Treatment of Chronic Hepatitis C in All Major Genotypes (GT 1-6) in as Short as 8 Weeks Media name/outlet 14 WFIE Country United States Date 8/3/17 Persons Fred Poordad Title AbbVie Receives U.S. FDA Approval of MAVYRET™ (glecaprevir/pibrentasvir) for the Treatment of Chronic Hepatitis C in All Major Genotypes (GT 1-6) in as Short as 8 Weeks Media name/outlet WMCTV.com Country United States Date 8/3/17 Persons Fred Poordad Title AbbVie Receives U.S. FDA Approval of MAVYRET™ (glecaprevir/pibrentasvir) for the Treatment of Chronic Hepatitis C in All Major Genotypes (GT 1-6) in as Short as 8 Weeks Media name/outlet 35 WSEE Country United States Date 8/3/17 Persons Fred Poordad Title AbbVie Receives U.S. FDA Approval of MAVYRET™ (glecaprevir/pibrentasvir) for the Treatment of Chronic Hepatitis C in All Major Genotypes (GT 1-6) in as Short as 8 Weeks Media name/outlet KWES NewsWest 9 Country United States Date 8/3/17 Persons Fred Poordad Title AbbVie Receives U.S. FDA Approval of MAVYRET™ (glecaprevir/pibrentasvir) for the Treatment of Chronic Hepatitis C in All Major Genotypes (GT 1-6) in as Short as 8 Weeks Media name/outlet KOTV Country United States Date 8/3/17 Persons Fred Poordad Title AbbVie Receives U.S. FDA Approval of MAVYRET™ (glecaprevir/pibrentasvir) for the Treatment of Chronic Hepatitis C in All Major Genotypes (GT 1-6) in as Short as 8 Weeks Media name/outlet WTRF Country United States Date 8/3/17 Persons Fred Poordad Title AbbVie Receives U.S. FDA Approval of MAVYRET™ (glecaprevir/pibrentasvir) for the Treatment of Chronic Hepatitis C in All Major Genotypes (GT 1-6) in as Short as 8 Weeks Media name/outlet WOWK Country United States Date 8/3/17 Persons Fred Poordad Title AbbVie Receives U.S. FDA Approval of MAVYRET™ (glecaprevir/pibrentasvir) for the Treatment of Chronic Hepatitis C in All Major Genotypes (GT 1-6) in as Short as 8 Weeks Media name/outlet KTVN Country United States Date 8/3/17 Persons Fred Poordad Title AbbVie Receives U.S. FDA Approval of MAVYRET™ (glecaprevir/pibrentasvir) for the Treatment of Chronic Hepatitis C in All Major Genotypes (GT 1-6) in as Short as 8 Weeks Media name/outlet KOAM TV Country United States Date 8/3/17 Persons Fred Poordad Title AbbVie Receives U.S. FDA Approval of MAVYRET™ (glecaprevir/pibrentasvir) for the Treatment of Chronic Hepatitis C in All Major Genotypes (GT 1-6) in as Short as 8 Weeks Media name/outlet KHQ Right Now Country United States Date 8/3/17 Persons Fred Poordad Title AbbVie Receives U.S. FDA Approval of MAVYRET™ (glecaprevir/pibrentasvir) for the Treatment of Chronic Hepatitis C in All Major Genotypes (GT 1-6) in as Short as 8 Weeks Media name/outlet 3 WRCB-TV Country United States Date 8/3/17 Persons Fred Poordad Title AbbVie Receives U.S. FDA Approval of MAVYRET™ (glecaprevir/pibrentasvir) for the Treatment of Chronic Hepatitis C in All Major Genotypes (GT 1-6) in as Short as 8 Weeks Media name/outlet Fox 19 Country United States Date 8/3/17 Persons Fred Poordad Title AbbVie Receives U.S. FDA Approval of MAVYRET™ (glecaprevir/pibrentasvir) for the Treatment of Chronic Hepatitis C in All Major Genotypes (GT 1-6) in as Short as 8 Weeks Media name/outlet WECT TV-6 Country United States Date 8/3/17 Persons Fred Poordad Title AbbVie Receives U.S. FDA Approval of MAVYRET™ (glecaprevir/pibrentasvir) for the Treatment of Chronic Hepatitis C in All Major Genotypes (GT 1-6) in as Short as 8 Weeks Media name/outlet KUSI.com Country United States Date 8/3/17 Persons Fred Poordad Title AbbVie Receives U.S. FDA Approval of MAVYRET™ (glecaprevir/pibrentasvir) for the Treatment of Chronic Hepatitis C in All Major Genotypes (GT 1-6) in as Short as 8 Weeks Media name/outlet Fox41.com Country United States Date 8/3/17 Persons Fred Poordad Title AbbVie Receives U.S. FDA Approval of MAVYRET™ (glecaprevir/pibrentasvir) for the Treatment of Chronic Hepatitis C in All Major Genotypes (GT 1-6) in as Short as 8 Weeks Media name/outlet 19 Action News Country United States Date 8/3/17 Persons Fred Poordad Title AbbVie Receives U.S. FDA Approval of MAVYRET™ (glecaprevir/pibrentasvir) for the Treatment of Chronic Hepatitis C in All Major Genotypes (GT 1-6) in as Short as 8 Weeks Media name/outlet WTOL-TV Country United States Date 8/3/17 Persons Fred Poordad Title AbbVie Receives U.S. FDA Approval of MAVYRET™ (glecaprevir/pibrentasvir) for the Treatment of Chronic Hepatitis C in All Major Genotypes (GT 1-6) in as Short as 8 Weeks Media name/outlet Kait 8 Country United States Date 8/3/17 Persons Fred Poordad Title AbbVie Receives U.S. FDA Approval of MAVYRET™ (glecaprevir/pibrentasvir) for the Treatment of Chronic Hepatitis C in All Major Genotypes (GT 1-6) in as Short as 8 Weeks Media name/outlet WVNS Country United States Date 8/3/17 Persons Fred Poordad Title AbbVie Receives U.S. FDA Approval of MAVYRET™ (glecaprevir/pibrentasvir) for the Treatment of Chronic Hepatitis C in All Major Genotypes (GT 1-6) in as Short as 8 Weeks Media name/outlet NBC12 Online Country United States Date 8/3/17 Persons Fred Poordad Title AbbVie Receives U.S. FDA Approval of MAVYRET™ (glecaprevir/pibrentasvir) for the Treatment of Chronic Hepatitis C in All Major Genotypes (GT 1-6) in as Short as 8 Weeks Media name/outlet KFMB-TV Country United States Date 8/3/17 Persons Fred Poordad Title AbbVie Receives U.S. FDA Approval of MAVYRET™ (glecaprevir/pibrentasvir) for the Treatment of Chronic Hepatitis C in All Major Genotypes (GT 1-6) in as Short as 8 Weeks Media name/outlet WDAM-TV Country United States Date 8/3/17 Persons Fred Poordad Title AbbVie Receives U.S. FDA Approval of MAVYRET™ (glecaprevir/pibrentasvir) for the Treatment of Chronic Hepatitis C in All Major Genotypes (GT 1-6) in as Short as 8 Weeks Media name/outlet WLBT Country United States Date 8/3/17 Persons Fred Poordad Title AbbVie Receives U.S. FDA Approval of MAVYRET™ (glecaprevir/pibrentasvir) for the Treatment of Chronic Hepatitis C in All Major Genotypes (GT 1-6) in as Short as 8 Weeks Media name/outlet WTOC TV Country Georgia Date 8/3/17 Persons Fred Poordad Title AbbVie Receives U.S. FDA Approval of MAVYRET™ (glecaprevir/pibrentasvir) for the Treatment of Chronic Hepatitis C in All Major Genotypes (GT 1-6) in as Short as 8 Weeks Media name/outlet News 9 Country United States Date 8/3/17 Persons Fred Poordad Title AbbVie Receives U.S. FDA Approval of MAVYRET™ (glecaprevir/pibrentasvir) for the Treatment of Chronic Hepatitis C in All Major Genotypes (GT 1-6) in as Short as 8 Weeks Media name/outlet Kuam News 8 Country Guam Date 8/3/17 Persons Fred Poordad